SPI-1620: Phase I data

Top-line data from Part 1 of a 2-part, open-label, dose-escalation, U.S. Phase I trial in 30 patients who have failed all standard therapy showed that IV SPI-1620 on days 1, 8, and 15 plus docetaxel o...